Insider activity at Apellis Pharmaceuticals, Inc. has been all selling for a year now: about $3.9 million from nine sellers, and zero buyers on the open market.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | DeLong Mark Jeffrey | Executive Officer | Sell | 368 | $22.15 | $8K | SEC |
| Jan 23, 2026 | Baumal Caroline | Executive Officer | Sell | 2,797 | $21.77 | $61K | SEC |
| Jan 23, 2026 | Chopas James George | Executive Officer | Sell | 2,064 | $21.77 | $45K | SEC |
| Jan 23, 2026 | DeLong Mark Jeffrey | Executive Officer | Sell | 3,371 | $21.77 | $73K | SEC |
| Jan 23, 2026 | Deschatelets Pascal | Executive Officer | Sell | 5,928 | $21.77 | $129K | SEC |
| Jan 23, 2026 | Francois Cedric | CEO | Sell | 27,192 | $21.77 | $592K | SEC |
| Jan 23, 2026 | Nicholson Nur | Executive Officer | Sell | 7,725 | $21.77 | $168K | SEC |
| Jan 23, 2026 | Sullivan Timothy Eugene | CFO | Sell | 10,287 | $21.77 | $224K | SEC |
| Jan 23, 2026 | Watson David O. | Executive Officer | Sell | 7,832 | $21.77 | $171K | SEC |
| Jan 21, 2026 | Baumal Caroline | Executive Officer | Sell | 1,882 | $19.79 | $37K | SEC |
| Jan 21, 2026 | Chopas James George | Executive Officer | Sell | 726 | $19.79 | $14K | SEC |
| Jan 21, 2026 | DeLong Mark Jeffrey | Executive Officer | Sell | 1,334 | $19.79 | $26K | SEC |
| Jan 21, 2026 | Deschatelets Pascal | Executive Officer | Sell | 909 | $19.79 | $18K | SEC |
| Jan 21, 2026 | Francois Cedric | CEO | Sell | 8,182 | $19.79 | $162K | SEC |
| Jan 21, 2026 | Nicholson Nur | Executive Officer | Sell | 2,203 | $19.79 | $44K | SEC |
In the last 12 months Apellis Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $3.9 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in APLS was filed on 2026-02-13.
No congressional trades in APLS were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).